Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alembic PharmaceuticalsBOM:533573 +0.31%75 EBITDA Margin % is 12.44% as of Mar. 2026, which is 35% below its 10-year median of 19.07. GuruFocus rates BOM:533573 with a GF Score™ of 75/100 and a GF Value™ of ₹1,054.49 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 959 Drug Manufacturers companies, Alembic Pharmaceuticals ranks better than 56.52% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Alembic Pharmaceuticals EBITDA Margin % Related Terms
Alembic Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:533573 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alembic Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alembic Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alembic Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Alembic Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alembic Pharmaceuticals (BOM:533573) has a EBITDA Margin % of 12.44% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alembic Pharmaceuticals and its competitors. This is 35% below median its historical median of 19.07. Over the past decade, Alembic Pharmaceuticals' EBITDA Margin % has ranged from 12.37 to 29.71. According to the industry distribution chart, Alembic Pharmaceuticals ranks #417 out of 959 companies in the Drug Manufacturers industry, placing it in the top 43.5%.
Is Alembic Pharmaceuticals' EBITDA Margin % too high?
Alembic Pharmaceuticals' current EBITDA Margin % of 12.44% is 35% below median its 10-year median of 19.07. Over the past 10 years, this metric has ranged from a low of 12.37 to a high of 29.71. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Alembic Pharmaceuticals' value of 12.44% is 0.4% below this industry median. Based on the distribution chart, Alembic Pharmaceuticals ranks #417 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Alembic Pharmaceuticals has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alembic Pharmaceuticals' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alembic Pharmaceuticals ranks #417 out of 959 companies for EBITDA Margin %. This puts Alembic Pharmaceuticals in the upper half of its industry. The industry median EBITDA Margin % is 12.49. Alembic Pharmaceuticals' value of 12.44% is 0.4% below this benchmark. Historically, Alembic Pharmaceuticals' own EBITDA Margin % has ranged from 12.37 to 29.71 over the past decade. While the company's 10-year median is 19.07 vs. the industry median of 12.49, Alembic Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alembic Pharmaceuticals's current EBITDA Margin % of 12.44% is 0.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alembic Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alembic Pharmaceuticals's current EBITDA Margin % is 12.44%, which is 35% below median its own 10-year median of 19.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alembic Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alembic Pharmaceuticals (BOM:533573) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,054.49, compared to a current price of ₹796.50 — trading 24.5% below its estimated fair value. The current EBITDA Margin % is 12.44%, which is 35% below median its 10-year median of 19.07 and 0.4% below the Drug Manufacturers industry median of 12.49. Alembic Pharmaceuticals' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Alembic Pharmaceuticals (BOM:533573), the current EBITDA Margin % is 12.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alembic Pharmaceuticals (BOM:533573) Overvalued in 2026?
Based on GuruFocus' analysis, Alembic Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹796.50 is trading 24.5% below its estimated GF Value™ of ₹1,054.49.
GuruFocus considers Alembic Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for BOM:533573:
EBITDA Margin %: 12.44% (35% below median its 10-year median of 19.07)
GF Value™: ₹1,054.49 vs. price of ₹796.50 (24.5% below fair value)
Industry Position: 0.4% below the Drug Manufacturers median (#417 of 959)
No single metric tells the full story. See the BOM:533573 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities.
75GF Score
Get the complete analysis for BOM:533573
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:533573 has been successfully added to your 
